George Washington University, School of Medicine, IntimMedicine Specialists, Washington, DC.
Columbia University Medical Center, New York, NY.
Menopause. 2020 Feb;27(2):150-155. doi: 10.1097/GME.0000000000001443.
TX-004HR is a low-dose estradiol (E2) softgel vaginal insert designed to be rapidly dissolving and mucoadhesive. This report describes the physical attributes and pharmacokinetic parameters of the softgel vaginal insert evaluated for the treatment of moderate to severe dyspareunia due to menopausal vulvar and vaginal atrophy.
In vitro dissolution studies with 25-μg E2 inserts were performed and media samples were analyzed for E2 by high-performance liquid chromatography. Effects of body position on E2 bioavailability were assessed in a phase 1, randomized trial of the 25-μg softgel capsule versus a reference product in which women remained supine after dosing (n = 16), and in a substudy (n = 16) in which women were ambulatory or seated after dosing. Estradiol C max, AUC0-24, and t max were measured by high-performance liquid chromatography-tandem mass spectroscopy. A phase 2, randomized study (n = 50) of 10-μg E2 versus placebo inserts assessed timing of capsule disintegration at days 1 and 15.
In vitro testing detected more than 80% of E2 in the dissolution medium by 15 minutes (first time point measured). In the phase 1 studies, baseline-corrected E2 plasma levels were not significantly different regardless of supine versus ambulatory/seated position after dosing: C max, 24.1 versus 34.3 pg/mL; AUC0-24, 77.6 versus 93.7 h · pg/mL; and t max, 2.1 versus 1.9 hours, respectively. In the phase 2 study, no remnants of the softgel capsule were found at day 1 (6 hours) after dosing and day 15. Vaginal discharge was minimal (1/48 women; 2.1%).
The presented data support rapid dissolution of the softgel capsule and similar E2 pharmacokinetic parameters regardless of body position after dosing.
TX-004HR 是一种低剂量雌二醇(E2)阴道软胶囊,设计为快速溶解和黏膜附着。本报告描述了正在评估用于治疗因绝经导致的外阴和阴道萎缩引起的中度至重度性交困难的软胶囊阴道插入物的物理特性和药代动力学参数。
进行了 25-μg E2 插入物的体外溶解研究,并通过高效液相色谱法分析介质样品中的 E2。在一项 25-μg 软胶囊与参比产品的 1 期随机试验中评估了体位对 E2 生物利用度的影响,其中女性在给药后保持仰卧位(n=16),并在一项亚研究中(n=16),女性在给药后可走动或坐着。通过高效液相色谱-串联质谱法测量雌二醇 C max、AUC0-24 和 t max。一项 10-μg E2 与安慰剂插入物的 2 期随机研究(n=50)评估了胶囊在第 1 天和第 15 天的崩解时间。
体外测试在 15 分钟内(第一次测量时间点)检测到超过 80%的 E2 在溶解介质中。在 1 期研究中,给药后仰卧位与走动/坐位之间的基线校正后雌二醇血浆水平没有显著差异:C max,24.1 与 34.3 pg/mL;AUC0-24,77.6 与 93.7 h·pg/mL;t max,2.1 与 1.9 小时,分别。在 2 期研究中,在给药后第 6 小时(第 1 天)和第 15 天,未发现软胶囊的残留物。阴道分泌物极少(48 名女性中有 1 名;2.1%)。
提供的数据支持软胶囊的快速溶解,以及给药后无论体位如何,E2 药代动力学参数相似。